BR112012007989B1 - uso de sulfonamidas para a preparação de um medicamento para a prevenção de diabetes - Google Patents

uso de sulfonamidas para a preparação de um medicamento para a prevenção de diabetes Download PDF

Info

Publication number
BR112012007989B1
BR112012007989B1 BR112012007989A BR112012007989A BR112012007989B1 BR 112012007989 B1 BR112012007989 B1 BR 112012007989B1 BR 112012007989 A BR112012007989 A BR 112012007989A BR 112012007989 A BR112012007989 A BR 112012007989A BR 112012007989 B1 BR112012007989 B1 BR 112012007989B1
Authority
BR
Brazil
Prior art keywords
diabetes
days
meraxin
day
reparixin
Prior art date
Application number
BR112012007989A
Other languages
English (en)
Portuguese (pt)
Inventor
Lorenzo Piemonti
Luisa Daffaonchio
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A filed Critical Dompé Farmaceutici S.P.A
Publication of BR112012007989B1 publication Critical patent/BR112012007989B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112012007989A 2009-10-06 2010-10-06 uso de sulfonamidas para a preparação de um medicamento para a prevenção de diabetes BR112012007989B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172365A EP2308485A1 (en) 2009-10-06 2009-10-06 Sulfonamides for the prevention of diabetes
PCT/EP2010/064920 WO2011042465A1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes

Publications (1)

Publication Number Publication Date
BR112012007989B1 true BR112012007989B1 (pt) 2019-10-22

Family

ID=41716341

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007989A BR112012007989B1 (pt) 2009-10-06 2010-10-06 uso de sulfonamidas para a preparação de um medicamento para a prevenção de diabetes

Country Status (24)

Country Link
US (2) US8846755B2 (https=)
EP (2) EP2308485A1 (https=)
JP (1) JP5745526B2 (https=)
KR (1) KR101737656B1 (https=)
CN (1) CN102639128B (https=)
AU (1) AU2010305384B2 (https=)
BR (1) BR112012007989B1 (https=)
CA (1) CA2776021C (https=)
CY (1) CY1117599T1 (https=)
DK (1) DK2485724T3 (https=)
EA (1) EA021788B1 (https=)
ES (1) ES2570463T3 (https=)
HR (1) HRP20160399T1 (https=)
HU (1) HUE028132T2 (https=)
IL (1) IL219038A (https=)
ME (1) ME02385B (https=)
MX (1) MX2012004087A (https=)
NZ (1) NZ599171A (https=)
PL (1) PL2485724T3 (https=)
RS (1) RS54693B1 (https=)
SI (1) SI2485724T1 (https=)
SM (1) SMT201600126B (https=)
WO (1) WO2011042465A1 (https=)
ZA (1) ZA201202462B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844528B2 (en) * 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
US11291641B2 (en) 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
EP4686469A1 (en) 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
ATE444286T1 (de) 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
PT1579859E (pt) 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes

Also Published As

Publication number Publication date
IL219038A (en) 2015-07-30
NZ599171A (en) 2014-03-28
HRP20160399T1 (hr) 2016-05-20
US8846755B2 (en) 2014-09-30
AU2010305384B2 (en) 2016-02-04
CN102639128A (zh) 2012-08-15
IL219038A0 (en) 2012-06-28
JP5745526B2 (ja) 2015-07-08
HUE028132T2 (en) 2016-11-28
KR20120083889A (ko) 2012-07-26
CY1117599T1 (el) 2017-04-26
US20130059908A1 (en) 2013-03-07
JP2013506703A (ja) 2013-02-28
DK2485724T3 (en) 2016-05-02
EA021788B1 (ru) 2015-08-31
PL2485724T3 (pl) 2016-07-29
CA2776021C (en) 2017-08-01
US9556115B2 (en) 2017-01-31
WO2011042465A1 (en) 2011-04-14
US20150011639A1 (en) 2015-01-08
KR101737656B1 (ko) 2017-05-18
ZA201202462B (en) 2013-06-26
AU2010305384A1 (en) 2012-04-26
RS54693B1 (sr) 2016-08-31
HK1174557A1 (en) 2013-06-14
EP2485724B1 (en) 2016-02-10
CA2776021A1 (en) 2011-04-14
SMT201600126B (it) 2016-07-01
ME02385B (me) 2016-09-20
EA201270512A1 (ru) 2012-11-30
SI2485724T1 (sl) 2018-12-31
MX2012004087A (es) 2012-08-23
ES2570463T3 (es) 2016-05-18
EP2308485A1 (en) 2011-04-13
CN102639128B (zh) 2014-02-26
EP2485724A1 (en) 2012-08-15

Similar Documents

Publication Publication Date Title
Fudickar et al. Propofol infusion syndrome: update of clinical manifestation and pathophysiology
Taniguchi et al. Effects of goal-directed fluid therapy on enhanced postoperative recovery: an interventional comparative observational study with a historical control group on oesophagectomy combined with ERAS program
BR112012007989B1 (pt) uso de sulfonamidas para a preparação de um medicamento para a prevenção de diabetes
CA3081224A1 (en) Use of carbamate compound for reducing or treating developmental disorders including fragile x syndrome, angelman syndrome or rett syndrome
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
CN119632973A (zh) 漆黄素制备治疗心脏有关疾病的药物中的应用
JP2019038858A (ja) ペマフィブラートを含有する医薬
CN104582701A (zh) 减轻体重的方法
Tavares et al. Hypokalemia and hyperkalemia: Two Sides of the Same Coin
CN109562179A (zh) N,n-双-2-巯基乙基间苯二甲酰胺的新用途
CN114984005B (zh) 硫酸舒欣啶在制备抗肾功能衰竭药物中的应用
Irefin et al. Postoperative adverse effects after recent or remote lithium therapy
Lloyd et al. Choreoathetosis in the setting of lithium toxicity
Masopust et al. Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson's disease
HK1174557B (en) Sulfonamides for the prevention of diabetes
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
US20040171594A1 (en) Use of bis-acid(5-androsten-17-one-3beta-hydroxyl)diester for manufacture pharmaceuticals
Acikalin et al. Lipid therapy in cardiovascular drug poisoning
White et al. Acute kidney injury
Mariana et al. Observations on the effectiveness of post-operative administration of nutrients and fluids in dogs and cats.
Jain et al. Unraveling the Role of Serum Chloride Level as a Strong Predictor of Outcomes in Patients with Heart Failure: A Systematic Review and Meta-Analysis: PO1443
Grecu et al. Observations on the effectiveness of post-operative administration of nutrients and fluids in dogs and cats
TW201338803A (zh) 用於治療寵物腎衰竭之醫藥組合物
CN119970718A (zh) 吲哚-3-甲醛在制备预防或治疗类风湿关节炎制剂中的应用
Guaraldi Cardiac imaging and safety evaluation of BMS747158, a novel PET myocardial perfusion imaging agent, in chronic myocardial compromised rabbits

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: DOMPE FARMACEUTICI S.P.A (IT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2010, OBSERVADAS AS CONDICOES LEGAIS.